March 29, 2018 / 6:57 AM / 6 months ago

BRIEF-Redx Pharma says temporarily interrupting patient accrual to phase 1/2a clinical study for porcupine inhibitor​

March 29 (Reuters) - Redx Pharma Plc:

* RXC004 CLINICAL TRIAL UPDATE

* ‍TEMPORARILY INTERRUPTING PATIENT ACCRUAL TO ITS PHASE 1/2A CLINICAL STUDY FOR PORCUPINE INHIBITOR, RXC004​

* CURRENT INTENTION TO PROPOSE PROTOCOL AMENDMENT THAT ENABLES DOSE- ESCALATION TO RE-START AT SIGNIFICANTLY LOWER DOSE LEVELS​ Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below